Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study.

We treated 166 patients suffering from recurrent urinary tract infections under double-blind conditions for 3 months with 1 capsule daily of either the immunostimulating bacterial extract (85) or a placebo (81), followed by a 3-month observation period without the test drugs. The bacterial extract exerted a significant beneficial curative action and long-term consolidative effect on the frequency of recurrent urinary tract infections with marked improvements in the characteristic signs and symptoms. It was significantly superior to placebo for the majority of the assessed parameters: number of recurrent urinary tract infections, bacteriuria, leukocyturia, erythrocyturia, nitrituria, albuminuria and casts in urine. Consumption of antibiotics, chemotherapeutics, urinary antiseptics or disinfectants was significantly less under active drug therapy compared to placebo. Tolerance was good with only 2 side effects reported in 2 patients (2%) in the active group compared to 11 among 5 (6%) in the placebo group. Therefore, the bacterial extract can be considered an efficient and well tolerated drug for the treatment of urinary tract infections, and their accompanying signs and symptoms, as well as for decreasing the risk of recurrences and the need for antibiotics and other antibacterial drugs.

[Treatment of peptic ulcer with i.v. ranitidine. A treatment possibility in special cases. Experiences from general practice]. / Behandlung der peptischen Ulkuserkrankung mit i.v. Ranitidin. Eine Behandlungsmöglichkeit in besonderen Fällen. Erfahrungen aus einer Allgemeinpraxis.

20 outpatients with acute peptic ulcer were treated with ranitidine 50 mg i.v. twice daily in an open trial. 92% of the duodenal ulcers and 80% of the gastric ulcers were healed after four weeks treatment. The rapid symptomatic improvement noted during the patients daily visits was particularly impressive. The results of our study show that the commonly practised intravenous treatment of peptic ulcers is also practicable with a modern drug possessing a clearly defined mode of action.